Project Grant R21DA060411
Award Date
8/1/24
Completion Date
7/31/26
Dollars Obligated
$236K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $360,720 to support a randomized controlled trial examining the use of extended-release injectable buprenorphine for the treatment of opioid use disorder (OUD) in individuals who use high-potency synthetic opioids. The primary objectives of this 5-year study are to: 1) compare abstinence and relapse rates between participants receiving...
This $1,476,750 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support a pilot randomized controlled trial to evaluate the use of the medication semaglutide as an adjunct treatment to buprenorphine for individuals with opioid use disorder (OUD). The study, to be conducted by Brigham & Women's Hospital Inc. over 2 years from September 2024 to August 2026, will assess semaglutide's impact on reducing...
This $197,748 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to develop and pilot an enhanced low-dose buprenorphine initiation (LDI) program to improve treatment outcomes for individuals with opioid use disorder (OUD), especially those using fentanyl. The key objectives of this 4-year project are to: 1) identify barriers to successful LDI completion through qualitative interviews, 2)...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the 93.279 Drug Use and Addiction Research Programs, provides $2,930,360 to evaluate the real-world effectiveness of telehealth-delivered buprenorphine (tele-buprenorphine) for treating opioid use disorder (OUD). The study aims to generate clinical guidance on optimizing tele-buprenorphine care, including assessing effectiveness for high-risk populations and addressing treatment disparities. The project will use...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $2,214,862 to Duke University to optimize and evaluate the efficacy of a co-packaged long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) and buprenorphine (XR-B) intervention for individuals in carceral and community re-entry settings. The study aims to develop the intervention protocol, evaluate implementation strategies to...
This $4,801,857 federal Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to compare the effects of different medications for opioid use disorder (MOUD) on neuroinflammation and neurocognition in people living with HIV (PLWH). The goal is to evaluate whether opioid antagonist MOUD (e.g., XR-naltrexone) have anti-inflammatory and neuroprotective effects compared to opioid agonist MOUD...
The National Institute on Drug Abuse (NIDA) awarded a $177,170 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Massachusetts Medical School (UMass Medical) for the "Implementation of Medications for Opioid Use Disorder in Massachusetts Jails" project. The funding will support a mixed-methods study to analyze the implementation of medications for opioid use disorder (MOUD) treatment in Massachusetts county jails. The research aims...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $844,475 to the University of Alabama at Birmingham (UAB) to test a bundled intervention to increase treatment uptake and reduce opioid overdoses among patients with opioid use disorder (OUD) after emergency department (ED) discharge. The intervention combines peer support, telehealth, buprenorphine prescription, and linkage to...
This is a Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $297,061 grant will support Boulder Care, Inc. in developing and testing workflows to leverage telehealth and low-cost technologies to increase access to buprenorphine treatment for opioid use disorder (OUD) in high-risk settings such as jails, prisons, emergency departments, and rural tribal areas. In Phase I, the project will develop and test...
This Project Grant award for $144,362.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to evaluate a pharmacist-integrated model of opioid use disorder (OUD) treatment in primary care settings to increase naloxone co-prescribing. The research aims to: 1) describe federal, state, and clinic-level policies and interventions impacting naloxone co-prescribing, 2) investigate care team knowledge and attitudes...